Urinary Sodium-Potassium Ratio May Signal Heart Health in RA
In patients with rheumatoid arthritis (RA), higher urinary sodium-to-potassium ratio and sodium excretion were correlated with impaired coronary microvascular perfusion and might serve as an indicator.
METHODOLOGY:
Researchers conducted a cross-sectional study to investigate whether sodium and potassium intake and the ratio between urinary sodium and potassium excretion were associated with cardiovascular disease markers in patients with RA.
They included 61 adults with RA (mean age, 62.4 years; 78.7% women; 65% reported a history of hypertension) from the outpatient department of a hospital in Greece.
Assessments included markers of inflammation, estimated glomerular filtration rate (eGFR), disease activity using the 28-joint Disease Activity score, and other relevant parameters.
Sodium and potassium excretion was calculated using 24-hour urine samples. Daily sodium intake was estimated assuming the urinary sodium excretion of 93%, and daily potassium intake was estimated assuming a gastrointestinal absorption of 77%.
Coronary microvascular perfusion was evaluated using the subendocardial viability ratio (SEVR) measured with applanation tonometry; arterial stiffness was evaluated using pulse wave velocity and an augmentation index normalised to 75 beats/min.
TAKEAWAY:
The 24-hour urinary sodium and potassium excretion corresponded to a daily salt and potassium mean intake of 6.7 and 2.1 g, respectively. The mean urinary sodium-to-potassium ratio was 2.4, with only two patients showing an optimal ratio of ≤ 1.
Urinary sodium excretion was significantly associated with high-density lipoprotein cholesterol levels (correlation coefficient [r], -0.309; P = .016) and uric acid levels (r, 0.301; P = .028).
Urinary potassium excretion was positively associated with the eGFR (r, 0.371; P = .004), whereas it was negatively associated with disease activity (r, -0.387) and systemic inflammation (r, -0.269; P < .05 for both).
Urinary sodium excretion (beta [β], -0.247; P = .034) and urinary sodium-to-potassium ratio (β, -0.247; P = .026) were independently and inversely correlated with SEVR. Neither urinary sodium nor potassium (or their ratio) was linked to markers of arterial stiffness.
IN PRACTICE:
"[The study] findings add new evidence to the growing body of evidence regarding the importance of dietary sodium and potassium intake in terms of cardiovascular health, in a well-defined population of patients with RA," the authors of the study wrote.
SOURCE:
This study was led by Panagiota Anyfanti, 3rd Department of Internal Medicine, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece. It was published online on August 01, 2025, in Clinical Rheumatology.
LIMITATIONS:
The findings were relevant only for patients with RA in the absence of a control group, thereby limiting generalisability. The associations observed in this cross-sectional study may have been influenced by several confounding factors, such as comorbidities and medication use. Reliable data on heart failure were unavailable.
DISCLOSURES:
An open access funding was provided by HEAL-Link Greece. The authors declared having no competing interests.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
What effect does Ozempic have on muscles?
Mice aren't people, but they have a lot in common with humans genetically. And the furry rodents are often used in preliminary studies to help answer questions about where human research should go. For University of Utah researchers, a recently completed mouse study published in the journal Cell Metabolism suggests the need to look more closely at whether the popular drug Ozempic and other semaglutide drugs could cause muscle weakness that needs to be addressed for those taking the medications to manage diabetes or lose weight. The researchers hail the medications as a 'significant breakthrough in pharmacological interventions to treat obesity.' But they note recent concerns that Ozempic and similar drugs cause 'a loss of lean mass, potentially compromising physical function and quality of life, particularly in those susceptible to sarcopenia.' Sarcopenia is the loss of muscle mass, strength and function associated with age. But there are also medical conditions that could lead to worries about weakened muscles, too, the study's senior author, Katsu Funai, an associate professor of nutrition and integrative physiology at the University of Utah College of Health, told Deseret News. The goal is not to downplay the importance of how Ozempic and related drugs can improve health by controlling blood sugar or causing weight loss, he added. But his team wants to point out that measures might be needed to protect against a potential negative side effect. If further study shows that a drug leads to weaker muscles — especially in a population that might be susceptible already to losing strength — then those folks might need tandem interventions that maintain or build muscle strength. Funai said that besides age, recent surgeries, disabilities and other conditions might increase the risk of losing muscle strength. And quality of life is very much affected by muscle loss, which can lead to falls, injuries and inactivity, impacting overall health and well-being. What the Ozempic study found It's generally assumed that loss of lean muscle leads to loss of muscle mass and weaker muscles. That may not be as straightforward as some believe. The university-led research found those losing weight with Ozempic also lost about 10% of lean mass, though not necessarily from skeletal muscles, but from tissue such as the liver, which shrank a lot. 'Loss of mass in metabolically active organs, such as the liver, is expected as part of healthy weight loss,' Ran Hee Choi, research instructor in nutrition and integrative physiology at University Health and co-first author on the study, said in a news release. But both mice and humans can see organ size change alongside weight without a similar change in function. 'It's unlikely that the observed lean mass loss represents a serious adverse effect,' said Takuya Karasawa, postdoctoral researcher in the University of Utah Molecular Medicine Program and co-first author on the study. But size of muscles and strength are very different things, Funai said. And loss of lean mass is not the same as muscle loss or its strength, either. The researchers found that even when a muscle stayed the same size, it in some cases lost strength, while in other muscles that didn't happen. What isn't known — and needs to be studied, Funai said — is whether weight loss can lead to loss of muscle strength in some people and, if so, who would be impacted. Funai emphasized again that their work in mice raises questions, but does not necessarily apply directly to humans. For one thing, as the study notes, rodents and people gain and lose weight differently. People with obesity are often less physically active, while having obesity doesn't usually make mice more sedentary. And the mice were given obesity through a high-fat diet for the study, while people have many different reasons for weight gain, including genetics, diet, sleep patterns and age. Funai said it is very common for people to not realize they have lost strength in their muscles, but when it's tested, the loss is clear. 'When they're opening a jar or when they have to do flights of stairs that they don't usually do or have to carry something, then they might notice. It's something that they may not be aware of' otherwise, he said. He added that the loss of muscle mass and loss of muscle strength were dose dependent and time dependent, meaning that how long and how much Ozempic was given mattered. And the dose that was higher and where loss was more sustained was higher than would be given to people. It was noteworthy that loss of muscle mass and loss of force or strength weren't always coupled and that fact was not uncommon. The study points out the need for clinical trials that directly look at whether muscle strength is lost and if so, in which populations, Funai said. And those studies should consider not just Ozempic and other semaglutide weight-loss drugs, but those in development, he added. While studies frequently consider lean mass loss, physical function is an important issue that may not be so straightforward, he said. But it's critically important for those who may be vulnerable to losing strength and gaining associated risks. Solve the daily Crossword
Gizmodo
3 hours ago
- Gizmodo
Engineering Breakthrough Opens Door to Cheap Hydrogen Power
As an alternative to fossil fuel combustion, hydrogen fuel cells hold tremendous promise. But they're also notoriously difficult and expensive to manage, which largely explains why we don't see them everywhere (or anywhere, for that matter, except for a few initiatives that are 'exploring' their efficiency). But that may soon change. In a Nature Materials paper published August 8, researchers announced the development of a new type of solid-oxide fuel cell (SOFC) that addresses an underlying problem for these contraptions: temperature. Hydrogen fuel cells, a type of SOFC, directly convert hydrogen gas into energy and water. This process, while very efficient and long-lasting, demands ridiculously high operating temperatures ranging from 1,292 to 1,472 degrees Fahrenheit (700 to 800 degrees Celsius). The new cell, however, works at just 572 degrees F (300 degrees C), less than half of what was previously required. 'Bringing the working temperature down to 300°C would slash material costs and open the door to consumer-level systems,' said Yoshihiro Yamazaki, study senior author and a materials engineer at Kyushu University in Japan, in a statement. Specifically, the team focused on re-engineering the electrolyte, a ceramic layer composed of different atomic structures arranged in a crystal lattice. In hydrogen fuel cells, positively charged hydrogen ions, or protons, travel across these crystalline pathways to convert hydrogen gas into energy and water. Normally, the fuel cell must operate under extremely high temperatures to work, which the researchers tried to bypass using chemical dopants—substances added to manipulate a material's physical properties—in combination with an appropriate oxide crystal. 'But this also comes with a challenge,' Yamazaki explained. 'Adding chemical dopants can increase the number of mobile protons passing through an electrolyte, but it usually clogs the crystal lattice, slowing the protons down.' After testing various candidates, the team locked in on two compounds, barium stannate and barium titanate. When doped with scandium at a temperature of 572 degrees F, the two materials displayed efficiency levels at par with existing SOFCs at much higher temperatures. Surprisingly, the scandium atoms latched onto oxygen atoms to form a 'wide and softly vibrating [molecular] highway' that enabled the protons to travel with an 'unusually low migration barrier,' Yamazaki explained. The two compounds used for this electrolyte are also softer than what's conventionally used to build such cells, he added, which was likely the reason the compounds easily absorbed the scandium dopant. 'Our work transforms a long-standing scientific paradox into a practical solution, bringing affordable hydrogen power closer to everyday life,' Yamazaki said. Compared to room temperatures, 572 degrees F is still very high. Nevertheless, this reduction is still significant and paints a promising future for bringing down operating temperatures even further—and also operating costs—for the widespread, practical implementation of SOFCs.
Yahoo
7 hours ago
- Yahoo
‘Remarkable' pancreatic cancer jab offers longer survival hope for patients
A vaccine that appears to slow the progression of one of the most deadly cancers could be manufactured in bulk, researchers say. The jab has given hope to patients after a trial found it increased the survival of participants with pancreatic cancer. Researchers described the findings as 'remarkable' and have already started testing the efficiency of the jab among a larger group of pancreatic and bowel cancer patients. The jab uses a new type of immunotherapy, designed to improve vaccine delivery to the lymph nodes, which help the body fight infections and disease. Pancreatic and bowel cancers frequently carry a mutation in a gene called KRAS, which plays a key role in tumour growth, and scientists developed the jab to recognise and attack this gene. The study, published in the journal Nature Medicine, tested the jab on 20 patients with pancreatic cancer and five with bowel cancer. When participants were followed up after 20 months, 68 per cent had developed strong immune responses specific to mutant KRAS tumour proteins. Participants who had the strongest immune responses lived and stayed cancer-free for longer than those with weaker responses. Some patients survived about two years and five months after receiving the vaccine. In comparison, just three in 10 people diagnosed with pancreatic cancer survive for a year. Pancreatic cancer has some of the poorest survival rates due to late detection. It doesn't usually cause symptoms in the early stages, and as it grows, it can cause tummy pain, yellowing of the skin, unexplained weight loss and changes in stools. Many patients see their cancer returning even after treatments such as radiotherapy and chemotherapy. But the trial showed the jab could help prevent the cancer from returning for more than 15 months. Unlike other cancer jabs which are personalised to individual patients, this vaccine, ELI-002 2P, has a single version which can be given to all patients meaning it can be manufactured in bulk and given more rapidly. Dr Dani Edmunds, research information manager at Cancer Research UK, said: 'It's promising to see that vaccines could help people with pancreatic and bowel cancer live cancer-free for longer.' 'More research is needed to understand why some people benefit from the vaccine while others don't, so that we can make sure we're beating cancer for everyone,' he added. Professor Richard Sullivan, director of the Centre for Conflict and Health Research at King's College London, has suggested more research is needed. 'There is some interesting science in this study, but this is a long way from proving any sort of clinical utility,' he said.
